All News
Can we withdraw treatment in post-menopausal osteoporosis?
d
EurekAlert!
Analysis of French claims data, found over half of women initiating oral bisphosphonates (BP) between 2015 and 2020 discontinued treatment for at least one year, which was associated with a 12% increase in fracture risk.
Read Article
Dual seropositivity and shared epitopes in RA: friends or foes?
Dual seropositivity (rheumatoid factor and/or anti-citrullinated protein antibodies) as well as shared epitope are known to be associated with poor prognosis and structural damage in RA.
Read Article
Nationwide turkish cohort study e.PULSE
347000+ pts
Gender based comorbidity analysis
Female asso w/ higher
-accompanying CTD OR 3.75
-asthma OR 2.06
-depression OR 2.38
-fibromyalgia OR 3.16
and lesser
- COPD OR 0.34
- ILD OR 0.60
-Malignancy OR 0.63
@RheumNow #EULAR2024 OP0175
Aurelie Najm AurelieRheumo ( View Tweet)
When to administrate the PCV13 in RA?
VACIMRA study 276pts randomized
PCV13 + MTX = 75% humoral response
PCV13 + MTX 1 month later = 88% humoral response
No diff on dis control & GCs or DMARDs use
#EULAR2024 @RheumNow AbstOP0140
Aurelie Najm AurelieRheumo ( View Tweet)
#EULARBest @RheumNow https://t.co/cCv88iTCTV
Aurelie Najm AurelieRheumo ( View Tweet)
ARGO trial Ph 2 RCT Sonelokimab IL-17A/Fi Nanobody
Wk 12, primary ACR50
ACR 50 SON 120 mg 46% 60 mg 46% PBO 20%
PASI 90 SON 120 mg 60% 60 mg 77% PBO 15%
MDA SON 60mg 47% PBO 20%
No new safety signal
#EULAR2024 @RheumNow AbstrOP0195 https://t.co/4W5KFi23za
Aurelie Najm AurelieRheumo ( View Tweet)
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PH 2/3 STUDY OF SHR0302, A SELECTIVE JAK 1 INHIBITOR, IN PATIENTS WITH ACTIVE AS - behaves like a JAK in AxSpA now as well as in RA - safety is clean/no new signals but where is the zoster? @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
Baseline predictors of D2TRA in naive recent onset RA 1000pts
-female sex
-higher joint count
-erosions
-pulmonary involvement
-depression
-fatigue
#EULAR24 AbstOP0118 @RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
COMPARATIVE SAFETY OF JAK INHIBITORS VERSUS TNF OR IL-17 INHIBITORS FOR CARDIOVASCULAR DISEASE, VENOUS THROMBOEMBOLISM AND CANCER IN PSORIATIC ARTHRITIS AND AXIAL - no signal of significant difference but channeling bias last few years @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
COMPARATIVE RISK OF MORTALITY IN NEW USERS OF PRESCRIPTION OPIOIDS FOR NON-CANCER PAIN: RESULTS FROM THE INTERNATIONAL PHARMACOSURVEILLANCE STUDY - HR 9-13 increased deaths narcotic use compared with codeine UK Boston Montreal >1 million pts included @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
3 pain clusters in AxSpA - tres intéressant @RheumNow #EULAR2024 https://t.co/ZgXvsxHlJu
Peter Nash drpnash ( View Tweet)
OP0202 looks at phenotypes of #RAILD in a cluster analysis
🌎Large multinational cohort
2⃣Two key clusters identified
📈Male sex, older age at RA & ILD onset, European ethnicity, smoking and CCP & RF positivity more frequent in cluster 1 vs 2
@RheumNow #EULAR2024 @Juge_P_A
Mrinalini Dey DrMiniDey ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty
Dr. John Cush RheumNow ( View Tweet)
GOLMePsA RCT early naive PsA
Golimumab or PBO in addition to MTX+IM GCs
No difference wk52
ACR20 GOL 76% PBO 55%
MDA GOL 55% PBO 41%
PBO arm received higher GC dose
No new safety signal
@RheumNow AbstOP0148 #EULAR2024 https://t.co/bj7YNXhssm
Aurelie Najm AurelieRheumo ( View Tweet)
📺 Join @RheumNow, @Yuz6Yusof & I for the Daily Recap over on @YouTube
⏩ https://t.co/D3HZGUdi9t
⏰ TODAY 18:00 CEST
👋 See you there!
#EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
Nationwide epi study of lymphoproliferative disorders in Sjogren's. All pts in France!
4 % prevalence
More in males and those with cryos and MGUS
#EULAR2024
@rheumnow
abst#OP0207 https://t.co/bEaWpTD7x3
Links:
Bella Mehta bella_mehta ( View Tweet)
Severe refractory Sjogrens - not in RCTs but some meds such as CD20 - Obinutuzumab, CART have been reported.
A summary of slides @RheumNow https://t.co/9HQRAj3rzt
Links:
Bella Mehta bella_mehta ( View Tweet)
CD40 and CD40L (CD154) inhibition
CD-40 monoclonal antibody
CD 40 Ligand blockade- Dazodalibep
@RheumNow https://t.co/n9CcrujVwa
Links:
Bella Mehta bella_mehta ( View Tweet)
#EULAR2024 POS0237 RNA-seq of muscle biopsy in inflammatory myopathy (IIM) showed distinct gene expressions underlying muscle damage between DM, Antisynthetase & PM. Potential targets for future therapeutics @RheumNow @IzukaShinji https://t.co/nf0pp2RhaE
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Current and future treatment in Sjogrens Syndrome @rheumnow #EULAR2024
Many failed trails - likely secondary to non validated outcomes.
3 major domains - sicca, extraglandular manifestations, constitutional https://t.co/cCYX1YCqG2
Links:
Bella Mehta bella_mehta ( View Tweet)